9.25
2.32%
-0.22
After Hours:
9.25
Centessa Pharmaceuticals plc ADR stock is currently priced at $9.25, with a 24-hour trading volume of 74,239.
It has seen a -2.32% decreased in the last 24 hours and a -13.95% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $9.58 pivot point. If it approaches the $9.19 support level, significant changes may occur.
Previous Close:
$9.47
Open:
$9.47
24h Volume:
74,239
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-151.09M
P/E Ratio:
-5.1105
EPS:
-1.81
Net Cash Flow:
$-160.51M
1W Performance:
-0.43%
1M Performance:
-13.95%
6M Performance:
+31.21%
1Y Performance:
+97.23%
Centessa Pharmaceuticals plc ADR Stock (CNTA) Company Profile
Name
Centessa Pharmaceuticals plc ADR
Sector
Industry
Phone
44 73 9178 9784
Address
The Dorothy Hodgkin Building Babraham, Research Campus Babraham, Cambridge
Centessa Pharmaceuticals plc ADR Stock (CNTA) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-17-23 | Initiated | SVB Securities | Outperform |
Aug-12-22 | Downgrade | Morgan Stanley | Overweight → Underweight |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Jun-03-22 | Downgrade | Jefferies | Buy → Hold |
Feb-11-22 | Initiated | Goldman | Neutral |
Centessa Pharmaceuticals plc ADR Stock (CNTA) Latest News
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares
GlobeNewswire Inc.
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares
GlobeNewswire Inc.
Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2023
GlobeNewswire Inc.
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga
SPS Commerce Posts Upbeat Results, Joins Masonite International, Impinj And Other Big Stocks Moving Higher On Friday
Benzinga
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
GlobeNewswire Inc.
Centessa Pharmaceuticals plc ADR Stock (CNTA) Financials Data
Centessa Pharmaceuticals plc ADR (CNTA) Net Income 2024
CNTA net income (TTM) was -$151.09 million for the quarter ending December 31, 2023, a +30.12% increase year-over-year.
Centessa Pharmaceuticals plc ADR (CNTA) Cash Flow 2024
CNTA recorded a free cash flow (TTM) of -$160.51 million for the quarter ending December 31, 2023, a +20.41% increase year-over-year.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings per Share 2024
CNTA earnings per share (TTM) was -$1.56 for the quarter ending December 31, 2023, a +32.47% growth year-over-year.
Centessa Pharmaceuticals plc ADR Stock (CNTA) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Anderson Karen M. | Chief People Officer |
Mar 25 '24 |
Option Exercise |
3.94 |
45,000 |
177,252 |
122,685 |
Anderson Karen M. | Chief People Officer |
Mar 25 '24 |
Sale |
11.88 |
51,160 |
607,960 |
71,525 |
Rotman Harris | SVP Regulatory Affairs |
Feb 01 '24 |
Sale |
8.10 |
4,267 |
34,574 |
62,625 |
Rotman Harris | SVP Regulatory Affairs |
Sep 20 '23 |
Option Exercise |
4.37 |
37,484 |
163,688 |
70,984 |
Rotman Harris | SVP Regulatory Affairs |
Sep 20 '23 |
Sale |
6.29 |
37,484 |
235,688 |
33,500 |
YVER ANTOINE | EVP & Chairman of Development |
Jun 01 '23 |
Sale |
4.45 |
6,500 |
28,949 |
783,066 |
Bush Tia L | Chief Quality Officer |
May 24 '23 |
Sale |
4.48 |
8,000 |
35,865 |
0 |
About Centessa Pharmaceuticals plc ADR
Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.
Cap:
|
Volume (24h):